2024-01-24 04:31:39 ET
Summary
- Sarepta Therapeutics is a biopharmaceutical company focused on developing gene therapy and RNA-targeted treatments for rare diseases such as Duchenne muscular dystrophy and Limb-girdle muscular dystrophy.
- The company's FDA-approved products, including Elevidys and three RNA-targeted injections, have shown strong financial results in Q3 2023.
- The possible expansion label for Elevidys granted by the FDA could extend the target age group, increasing its growth potential.
- SRPT appears to trade at a slight premium relative to peers, but its promising revenue growth justifies it.
- I am bullish on SRPT's long-term prospects and rate the shares a "buy" for long-term investors.
...
Read the full article on Seeking Alpha
For further details see:
Sarepta Therapeutics: Leading The Way In DMD Treatment With Gene Therapy Innovations